Alexion, other drugmakers pay $123M to settle kickback claims

Prosecutors alleged that beginning in 2010, Alexion set up a fund to cover the out-of-pocket costs of its blockbuster drug Soliris.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.